Max Delbruck Center for Molecular Medicine:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Max Delbruck Center for Molecular Medicine - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12383
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Max Delbruck Center for Molecular Medicine (MDC) is a biomedical research center that offers translating discoveries from molecular research into applications. The company’s research area services offer for cancer research, cardiovascular and metabolic disease, diseases of the nervous system, medical systems biology and clinical research. Its labs and fellows include research labs and fellows. MDC research labs offer biochemistry and proteomics, cancer, cardiovascular research, cell biology, computational biology, developmental biology, epidemiology and gene engineering. The company’s scientific infrastructure offers technology platforms, technology transfer, support services and animal facilities. MDC is headquartered in Berlin, Germany.

Max Delbruck Center for Molecular Medicine – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 11
Licensing Agreements 13
Fate Therapeutics Enters into Option and Licensing Agreement with Max Delbruck Center 13
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 14
Formula Pharma Enters into Licensing Agreement with Max Delbruck Center for Molecular Medicine 15
Berlin Cures Enters into Licensing Agreement with Charite and Max Delbruck Center 16
Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 17
Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 18
Max Delbruck Center for Molecular Medicine – Key Competitors 19
Max Delbruck Center for Molecular Medicine – Key Employees 20
Max Delbruck Center for Molecular Medicine – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Government and Public Interest 22
Dec 13, 2017: Molecular Chaperones Shown to Assist in the Fight against Huntington Disease 22
Product News 24
Jul 25, 2017: BeLOVE launches: first patients recruited for large study in Germany’s capital city of Berlin 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Key Facts 2
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Max Delbruck Center for Molecular Medicine, Deals By Therapy Area, 2012 to YTD 2018 8
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 11
Fate Therapeutics Enters into Option and Licensing Agreement with Max Delbruck Center 13
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 14
Formula Pharma Enters into Licensing Agreement with Max Delbruck Center for Molecular Medicine 15
Berlin Cures Enters into Licensing Agreement with Charite and Max Delbruck Center 16
Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 17
Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 18
Max Delbruck Center for Molecular Medicine, Key Competitors 19
Max Delbruck Center for Molecular Medicine, Key Employees 20

List of Figures
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Max Delbruck Center for Molecular Medicine:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fukoku Mutual Life Insurance Company:企業の戦略・SWOT・財務情報
    Fukoku Mutual Life Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Fukoku Mutual Life Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Biodesix Inc:医療機器:M&Aディール及び事業提携情報
    Summary Biodesix Inc (Biodesix) is a molecular diagnostics company which discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests in oncology for patients and doctors to enable precision medicine. These tests are used for early detection of diseases, diagnosis a …
  • Alembic Pharmaceuticals Ltd (APLLTD):企業の財務・戦略的SWOT分析
    Summary Alembic Pharmaceuticals Ltd (APL) is a pharmaceutical company which manufactures and markets generic pharmaceutical products. The company’s active pharmaceutical ingredients include macrolides, NSAIDs, and other drugs. It also offers branded formulations in the areas of antibiotics and antib …
  • Genedrive Plc (GDR):企業の財務・戦略的SWOT分析
    Genedrive Plc (GDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Resonance Health Ltd (RHT):医療機器:M&Aディール及び事業提携情報
    Summary Resonance Health Ltd (Resonance Health) is a healthcare solution provider that offers non-invasive medical imaging software and services. The company offers FerriScan analysis software for the measurement of liver iron concentration (LIC); FerriScan with Cardiac T2* dual analysis service to …
  • Weihai Guangtai Airport Equipment Co., Ltd.:企業の戦略・SWOT・財務情報
    Weihai Guangtai Airport Equipment Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Weihai Guangtai Airport Equipment Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Vista Gold Corp.:企業の戦略・SWOT・財務情報
    Vista Gold Corp. - Strategy, SWOT and Corporate Finance Report Summary Vista Gold Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Magnus Life Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Magnus Life Ltd (Magnus) is a biomedical organization that funds, builds and manages companies to translate science into therapeutics and devices. The organization in involved in developing therapies for the treatment for obstetric conditions and pathologies of pregnancy including placental …
  • Enel Generacion Chile SA:発電所・企業SWOT分析
    Enel Generacion Chile SA - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • Shenandoah Valley Electric Cooperative Inc:企業の戦略的SWOT分析
    Shenandoah Valley Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • Ineos Group AG-石油・ガス分野:企業M&A・提携分析
    Summary Ineos Group AG (Ineos) is a chemical company, which manufactures and sells petrochemicals, specialty chemicals and oil products. The company’s products include engineering thermoplastic resins, chlor-alkali chemicals, PVC products, films and compounds; and melamine resins for coating, specia …
  • Ali Baba:企業の戦略・SWOT・財務情報
    Ali Baba - Strategy, SWOT and Corporate Finance Report Summary Ali Baba - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Universal Display Corp (OLED):企業の財務・戦略的SWOT分析
    Summary Universal Display Corp (UDC) is a clean technology company that conducts research, develops and markets organic light emitting diode, technologies and materials. The company offers PHOLED materials which are used in making OLED displays and lighting panels. It provides technologies such as F …
  • DrillingInfo Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary DrillingInfo Inc (DrillingInfo) is an oil and gas service provider that offers upstream drilling services and oilfield services. The company's products include DI courthouse, DI analytics, DI basic, DI engineering, DI international product line, DI geodata services, DI rig analytics, DI play …
  • Connect Group PLC (CNCT):企業の財務・戦略的SWOT分析
    Connect Group PLC (CNCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • gel-e Inc:製品パイプライン分析
    Summary gel-e Inc (gel-e), formerly Remedium Technologies Inc is a medical device company that offers products for the treatment of acute wounds. The company's products include spray foams, bandages, gels, films, and band-aids. It offers proprietary technology platform that helps in development of w …
  • Tainergy Tech Co Ltd (4934):電力:M&Aディール及び事業提携情報
    Summary Tainergy Tech Co Ltd (Tainergy) is a renewable energy company that designs, develops, manufactures and markets solar energy products. The company provides products such as solar deionized water systems, multi-crystalline silicon solar cell, standard solar modules, solar module with build in …
  • Metabolon Inc-医療機器分野:企業M&A・提携分析
    Summary Metabolon Inc (Metabolon) is a health technology company that develops clinical diagnostic tests for healthcare markets. The company’s products include non-alcoholic steatohepatitis test, GFR test, quantose IGT test, prostarix and prostarix plus tests, among others. Its quantose IR test is a …
  • Philippine Long Distance Telephone Co (TEL):企業の財務・戦略的SWOT分析
    Philippine Long Distance Telephone Co (TEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Country Club Hospitality & Holidays Ltd.
    Country Club Hospitality & Holidays Ltd. - Strategy, SWOT and Corporate Finance Report Summary Country Club Hospitality & Holidays Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆